Targeted drug study for moderate to severe Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Weigh at least 88 pounds (40 kg)
- Had a Crohn's disease diagnosis for at least 3 months
- Active symptoms with a score of 220 or higher on a standard Crohn's disease activity scale
- Visible inflammation in the intestines shown by a scope test (endoscopy), with a severity score of at least 4 or 6 depending on location
- Crohn's disease not responding to or not tolerating standard treatments, such as biologics or other targeted drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
This trial tests whether combining vedolizumab with adalimumab or ustekinumab helps people with moderate to severe Crohn's disease who haven't responded to other treatments. It aims to find better ways to manage symptoms and improve quality of life.
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.